Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$20.22 USD
-0.07 (-0.34%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $20.22 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Brokerage Reports
Catalyst Pharmaceuticals, Inc. [CPRX]
Reports for Purchase
Showing records 361 - 380 ( 428 total )
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
2Q14 Recap - Firdapse Data Coming in Late September
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Firdapse Enrollment Complete - On Track for 3Q14 Data
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
DMC Continues Firdapse Trial - Expected, but Still the Best Outcome
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
4Q13 Recap - Enrollment Completing Soon; Buy for 3Q14 Data
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
3Q13 Recap - Firdapse Trial Enrollment Continues, Data Coming in 2Q14
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S